RxDoctor Payments Data

Candice Baker

Family · Clinton, MONPI 1841288834

Payments from drug & device makers

$1,058in general payments, 2019–2025

Across 57 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Otsuka America Pharmaceutical, Inc.$171
  • Lilly USA, LLC$152
  • Novo Nordisk$101
  • AstraZeneca$86
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$79
  • plus $234 from 11 others

What the payments were for

  • Food & beverage$1,058100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,058 in reported general payments places this provider in the 65th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$1,515
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$54,879
EliquisApixaban54$23,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,850
RybelsusSemaglutide16$15,646
JardianceEmpagliflozin36$15,614
JanuviaSitagliptin Phosphate11$14,023
TrulicityDulaglutide13$12,987
XareltoRivaroxaban31$12,983
Combivent RespimatIpratropium/Albuterol Sulfate14$12,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$10,001
BrilintaTicagrelor18$8,190
Spiriva RespimatTiotropium Bromide12$6,479
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$5,126
EntrestoSacubitril/Valsartan11$4,144
Advair HfaFluticasone Propion/Salmeterol11$4,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$101$70,52572 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta$18$37,33474 claims
PfizerEliquis, Dilantin$38$26,06966 claims
Lilly USA, LLCTrulicity$152$12,98713 claims
AstraZenecaBrilinta$86$8,19018 claims
NovartisEntresto$31$4,14411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,812 family providers in Missouri.

Other family in Clinton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →